AbbVie Inc. Available-for-sale Securities, Gross Realized Gain (Loss)
AbbVie Inc. (ABBV) reported Available-for-sale Securities, Gross Realized Gain (Loss) of $90.00 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-02-21.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet · last filed 2020-02-21
- AbbVie Inc. available-for-sale securities, gross realized gain (loss) for the quarter ending 2017-12-31 was $41.00M.
- AbbVie Inc. available-for-sale securities, gross realized gain (loss) for the quarter ending 2017-09-30 was $39.00M.
- AbbVie Inc. available-for-sale securities, gross realized gain (loss) for fiscal 2017 was $90.00M.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss) 3 month | Available-for-sale Securities, Gross Realized Gain (Loss) 6 month | Available-for-sale Securities, Gross Realized Gain (Loss) 9 month | Available-for-sale Securities, Gross Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $41.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $80.00M derived: sum of 2 quarters · filed 2020-02-21 | $90.00M 10-K · filed 2020-02-21 | |
| 2017-09-30 | $39.00M 10-Q · filed 2017-11-07 | $49.00M 10-Q · filed 2017-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |